Atrium Therapeutics corrects post-PIPE share count to 21,571,507, including make-whole spin-off shares

Atrium Therapeutics, Inc.

PIPE securities purchase agreement dated Oct. 7, 2026 with accredited investors covers 5,170,384 common shares plus pre-funded warrants for up to 1,134,930 shares.
Amendment No. 1 restates shares outstanding after the offering as 21,571,507, correcting the number in the original Oct. 8, 2026 Form 8-K; no other information revised.
That total includes shares issued to settle make-whole equity awards granted in connection with the Company's spin-off from Avidity Biosciences, Inc.
Closing of the offering remains subject to conditions; the company flags risk that it or the PIPE Investors may fail to satisfy them.
Amendment signed Oct. 9, 2026 by Chief Executive Officer Kathleen Gallagher.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.